Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Depalgos is a fixed-dose combination small molecule analgesic drug containing oxycodone hydrochloride, a semi-synthetic mu-opioid receptor agonist, and paracetamol (acetaminophen), a non-opioid analgesic. It is primarily indicated for the management of moderate to severe acute pain, particularly in the postoperative setting following orthopedic or general surgery. Oxycodone acts as an agonist at mu-opioid receptors in the central nervous system, altering the perception of and emotional response to pain. Paracetamol provides complementary analgesia, likely through the inhibition of prostaglandin synthesis in the central nervous system. Marketed in Italy by Molteni Farmaceutici, Depalgos is available in multiple strengths as film-coated and effervescent tablets, providing a synergistic approach to pain control by combining opioid and non-opioid mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxycodone + paracetamol (Molteni Farmaceutici).